Research Triangle Park, North Carolina — According to state and local economic development sources Jaguar Gene Therapy plans to invest $125,000,000.00 to build out 174,000 square feet of new space in Research Triangle Park. The company plans to occupy the new space in Research Triangle Park, on or about November 1, 2022. According to the company website Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by a proven management team including former AveXis leadership, Jaguar Gene Therapy has the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments. The company is supported by a group of visionary investors, including Deerfield Management, Eli Lilly and Company, ARCH Venture Partners, Goldman Sachs and Nolan Capital. Jaguars current pipeline utilizes the proven and well-characterized AAV9 vector to target diseases in patient populations with large unmet need, including galactosemia, genetic causes of autism spectrum disorder and Type 1 diabetes. Additionally, Axovia Therapeutics, a majority-owned subsidiary of Jaguar Gene Therapy that is focused on creating transformative therapies for ciliopathies, is advancing a gene therapy treatment for BBS1, a subset of Bardet-Biedl syndrome (BBS).

To learn more about Jaguar Gene Therapy, visit http://jaguargenetherapy.com/

Company Contact:
Andrew Knudten, Chief Operating Officer
https://www.linkedin.com/in/andrew-knudten-63996/
847-732-4916

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved